Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycopene + beta-sitosterol is a combination dietary supplement marketed primarily for **prostate health** and the management of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Beta-sitosterol is a plant-derived phytosterol that can inhibit 5-α-reductase, reducing the conversion of testosterone to dihydrotestosterone, a hormone involved in prostate enlargement, and may exert pro-apoptotic and anti-inflammatory effects in prostate tissue[1][2]. Lycopene is a carotenoid antioxidant associated with modulation of oxidative stress and potential lipid and blood pressure benefits. The combination is typically positioned as a non-pharmaceutical alternative or adjunct for men with mild urinary symptoms due to BPH, with observed benefits including modest improvement in IPSS (International Prostate Symptom Score), decreased nocturia, and reduced LDL cholesterol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lycopene + beta-sitosterol.